Technology Catalogue – University of Copenhagen

Forward this page to a friend Resize Print Bookmark and Share

Business Collaboration > Commercialisation > Technology Catalogue

Technology Catalogue

The University of Copenhagen (UCPH) owns a number of technologies, which external researchers and companies can purchase a license to use. Below are descriptions of some of the technologies that are currently available.

You are also welcome to contact the Tech Office to get a full overview of current inventions within a specific field of study.

Current licensing opportunities

Licensing opportunity:
Antibody mimetics – a new class of small peptides that target proteins with ultrahigh affinity and specificity

A new class of customized antibody equivalents designed to recognize almost any surface of a protein.

Being small peptides, the antibody mimetics can be produced using standard peptide synthesis methods.

Due to their high affinity and specificity, they have versatile use in detection, diagnosis and therapy.

Link: Read the full description.

Patent Application Number: Pending

Contact: Michael Abildgren, Commercial Officer  

Licensing opportunity:
New synthetic antibiotics against MRSAs: Piperazine Inhibitors of Bacterial Gyrase and Topoisomerase IV

Novel class of antibiotic compounds that are effective against methicillin-resistant Staphylococcus aureus (MRSA) and other Gram-Positive strains Tech Benefits: One antibiotic can potentially target two different type IIA topoisomerases found in bacteria. Consequently, development of resistance would require mutations to occur in both of the corresponding genes (gyrA and parC).

DNA gyrase is not found in humans, and the human topoisomerases have distinct differences from the bacterial counterparts and are generally not affected by bacterial topoisomerase inhibitors.

This new class of antibiotics possesses a simple chemical structure, which facilitates its rapid non costly preparation via chemical synthesis

Link: Read the full description.

Patent Application Number: PCT/EP2016/000357

Contact: Peter Stein Nielsen, Commercial Officer  

Licensing opportunity:
Immortalized cell culture of ER-positive human breast epithelial cells

Researchers at the University of Copenhagen have developed a viable breast cell culture system expressing endogenous estrogen receptors for use in clinical and basic research.

The researchers have used immortalized ER-positive human breast cells and thereby allowing for both long term study and screening of drug candidates. Understanding the taxonomy and evolution of breast cancer rely on using normal cell types as a reference; however in current cell cultures the steroid receptor expression from normal breast cells is lost within a few days. There is a need for a viable breast cell culture system expressing endogenous estrogen receptors for use in clinical and basic research.

The assay for investigating normal breast cells involves isolating and tracking ER-positive human breast cells by FACS, using certain cell markers and releasing ER-positive cells from growth restraint by using inhibitors of TGF-β signaling.

Link: Read the full description.

Patent Application Number: PA 2015 70274

Contact: Maj Hilligsøe, Commercial Officer  

Licensing opportunity:
On demand release system of antibiotics on surfaces of implant and medical equipment

The University of Copenhagen and the Danish Technical University have developed an on-demand release system of surface attached proactive antibiotics with the aim of preventing biofilm formation on implants and medical devices. The new technology is designed to release protective antibiotics only in response to the presence of infecting pathogens.

Bacterial infections caused by microorganisms colonizing the surface of surgical implants, so called biofilm, are a serious problem in modern implant surgery. In the biofilm mode, bacteria attain the highest levels of multiple resistances to our present assortment of antibiotics and an almost unlimited capacity to evade immunity and survive in the infected host. Thus new preventive measures are needed that can eliminate bacteria, before they have formed biofilm on the implant.

Various methods, such as impregnating the device material with bactericidal components along with different coating strategies, have been developed using lipase-sensitive linkages, such as fatty acid esters or anhydrides. Extracellular lipases are particularly abundant at sites of bacterial infections, and the new on-demand system will only release antibiotic in response to the initial steps of the surface colonization, where the amassing bacteria are maximally susceptible to antibiotics.

The chosen antibiotic component is (but not limited to Ciprofloxacin), because of its function as a broad-spectrum antibiotic. The coated surfaces will keep their antibiotic properties intact in the absence of bacteria.This method can be implemented across a wide range of implantable devices and products due to the polymer being an integrated part of the invention.

Link: Read the full description.

Patent Application Number: Pending

Contact: Niels Lysholm Engelhard, Senior Commercial Officer    

Licensing opportunity:
Method for increasing protein stability and small molecular API solubility

The University of Copenhagen has developed a novel method of drastically increasing the thermal stability of protein, allowing for heating to 121 degrees Celcius without visible aggregation.

Problems of solubility and stability of novel small molecule drug candidates and novel protein/peptide based drug candidates may reduce drug efficacy, and induce toxicity or immunogenicity as well as increasing production costs, and thereby risking that novel treatments never reach the market.

The new technology, which implies addition of non-cytotoxic nanoparticles to the formulation, leads to increased protein thermal stability and significantly increases solubility of poorly soluble APIs. This non-cytotoxic, low cost method requires no additional steps and may be used in any formulation.

Link: Read the full description.

Patent Application Number: PCT/DK2015/188838 and PA 2014 70354

Contact: Maj Hilligsøe, Commercial Officer  

Licensing opportunity:
New field free pumping CE-MS interface

The University of Copenhagen has developed a novel CE-MS interface, which offers minimal band broadening, stable electrical contact, high sensitivity and furthermore is simple to produce in a cost-efficient manner. Coupling of CE to MS offers the better of two worlds in proteomic studies, where the high-resolution separations of CE are combined with the high detection selectivity and sensitivity of MS. Despite the fact that CE-MS interfaces have evolved over the past two decades, CE-MS is still not used as a routine technique in laboratories worldwide. The main problem with CE-MS interfaces is the requirement of establishing a stable electric contact for the electrophoretic separation, at the outlet of the capillary, which does not compromise the separation performance or sensitivity. The separation performance can easily be destroyed by small dead volumes at the electric contact since the sample volume is in the range of a few nL. The separation performance will be influenced if an external pressure has to be applied during the separation to pump the sample towards the MS.

Current liquid junction CE-MS interfaces requires application of external pressure, which induces band broadening that affects separation efficiency. This adds to complexity in the production process and offers poor mechanical stability. This means there is a need for a new CE-MS design.

The new technology developed at University of Copenhagen is based on forming a crack/fracture along the capillary, with an opening less than 2 µm in width. The submicron fracture both provides electric contact and as well generates field free pumping towards the MS. This unique property is related to the increased surfaces-to-volume ratio of the fracture, compared to that of the separation capillary.

The new CE-MS design has big advantages: Field- free pumping towards the MS, minimal band broadening, stable electrical contact up till 300 mA, and a good mechanical stability. The production process is simple, using known techniques.

The technology has been tested and it provides better performance both with regard to separation performance, sensitivity as well robustness of the CE-MS methods when compared with commercial solutions on the market

Link: Read the full description.

Patent number: PCT/DK2015/050178

Contact: Niels Lysholm Engelhard, Senior Commercial Officer